UK researchers have found that tocilizumab, a drug commonly used to treat rheumatoid arthritis, may offer new hope for people with treatment-resistant depression. Early trial results suggest the immunotherapy could help patients who haven't responded to traditional antidepressants.

Depression affects millions worldwide, and many struggle to find effective treatments. This breakthrough discovery opens a new avenue for those who've exhausted conventional options, potentially transforming mental health care. Read the full story →

Today's takeaway: Sometimes the answer to one illness holds the key to treating another—and this discovery could change lives for thousands living with depression.